top of page

CFE Urges Treasury to Narrow China Investment Restrictions to Protect Access to Lifesaving Medicines

3 hours ago
3 min read

The Center for a Free Economy (CFE) has submitted formal comments to the U.S. Department of the Treasury urging the agency to narrow proposed restrictions on American biotechnology investments in China. CFE warned that overly broad restrictions could discourage pharmaceutical innovation, put American companies at a competitive disadvantage, and limit Americans' access to lifesaving medicines without providing meaningful national security benefits.


The comments respond to Treasury's proposed Outbound Investment Security Program Regulations, which would implement the Comprehensive Outbound Investment National Security (COINS) Act. The proposal would expand restrictions on certain American investments involving Chinese biotechnology companies, including activities related to pharmaceutical compounds, vaccines, and cell and gene therapies.


CFE supports preventing American investments from strengthening the military, intelligence, and surveillance capabilities of foreign adversaries. However, the organization is urging Treasury to distinguish between technologies presenting genuine national security threats and ordinary commercial pharmaceutical research.


CFE's Formal Regulatory Comments


CFE submitted its comments as part of Treasury's rulemaking process, recommending targeted changes to preserve legitimate pharmaceutical research and investment while protecting national security.


Submitted to: U.S. Department of the Treasury, Office of Investment Security

Docket Number: TREAS-DO-2026-0595

RIN: 1505-AC94

Re: Outbound Investment Security Program Regulations, 31 CFR Parts 850 and 851


Broad Biotechnology Restrictions Could Harm American Patients


Pharmaceutical innovation depends on private investment and international research partnerships to identify promising treatments and bring new medicines to market. American companies frequently collaborate with foreign biotechnology firms to access drug candidates and advance research that could benefit patients in the United States.


China has become a significant participant in global pharmaceutical development. According to Reuters, Chinese biotechnology licensing deals reached approximately $115 billion worldwide in 2025, while nearly half of U.S. foreign drug-licensing deals involved Chinese companies.


Treasury's proposal could complicate certain equity investments, joint ventures, and financing arrangements involving Chinese biotechnology companies. Although traditional pharmaceutical licensing agreements generally fall outside the proposed restrictions, broader prohibitions could reduce capital available for early-stage research and discourage American participation in promising drug development projects.


CFE's comments warn that restricting commercial pharmaceutical research without a clear national security justification could delay new treatments and limit the options available to American patients.


Investment Restrictions Could Benefit Foreign Competitors


Limiting American biotechnology investments would not necessarily prevent Chinese companies from continuing their research or securing financing from other countries.


European pharmaceutical companies and other international competitors could pursue opportunities that American firms would be prohibited from financing. Such restrictions could redirect pharmaceutical development opportunities away from the United States without substantially reducing national security risks.


Uncertainty surrounding prohibited transactions could further discourage legitimate investment, increase compliance costs, and make financing more difficult for biotechnology companies. Pharmaceutical development already requires substantial capital, years of clinical testing, and significant financial risk.


CFE is urging Treasury to consider whether specific restrictions would meaningfully strengthen national security or primarily disadvantage American companies while allowing foreign competitors to pursue the same opportunities.


CFE Recommends Five Changes to the Proposed Rule


In its formal comments, CFE outlined five recommendations for Treasury to consider before finalizing the regulations.


  1. Narrow the scope of covered pharmaceutical technologies. Revise proposed Section 851.226(r)(4) to focus on biotechnology activities presenting identifiable national security risks rather than broadly encompassing commercial pharmaceutical research.

  2. Preserve legitimate research partnerships. Clarify the treatment of traditional pharmaceutical licensing agreements and other commercial arrangements that do not materially support foreign military or intelligence capabilities.

  3. Consider consequences for American patients. Evaluate whether the proposed restrictions could delay drug development, discourage investment in promising treatments, or limit Americans' access to new medicines.

  4. Avoid unnecessary competitive disadvantages. Assess whether prohibiting American investments would redirect pharmaceutical opportunities to foreign competitors without substantially improving national security.

  5. Establish predictable compliance standards. Provide clear definitions and practical guidance allowing American companies to determine which investments are permissible.


These recommendations would allow Treasury to address sensitive technologies while reducing unnecessary barriers to legitimate commercial pharmaceutical research.


CFE Takeaway


Protecting American national security should not come at the expense of pharmaceutical innovation or patients' access to lifesaving medicines. Treasury should adopt narrowly tailored biotechnology investment restrictions that address genuine security threats while preserving legitimate commercial research and international collaboration.


CFE's formal comments urge Treasury to avoid unnecessary restrictions that could disadvantage American companies, discourage private investment, and delay the development of new treatments. A more targeted approach would better protect national security while allowing American patients to benefit from continued advances in pharmaceutical innovation.

 
 
 

Comments


Join our mailing list

  • X
  • Facebook
  • Instagram
  • Youtube
  • LinkedIn
CFE logo.png

© 2026 Center for a Free Economy

bottom of page